World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
50
Citations
13023
World Ranking
4402
National Ranking
1702

Fengcai Zhu publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Fengcai Zhu sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 216 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Fengcai Zhu D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Fengcai Zhu sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 50 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Fengcai Zhu is affiliated with the Centers for Disease Control and Prevention in the United States, focusing primarily on the field of medicine with a significant emphasis on infectious diseases. Their research portfolio includes more than 350 publications, with subfields spanning infectious diseases, epidemiology, health, genetics, and immunology.

Their scientific contributions largely revolve around SARS-CoV-2 and COVID-19 research, which constitutes a substantial portion of their work. Other key research topics include COVID-19 clinical research studies, vaccine coverage and hesitancy, virus-based gene therapy research, viral gastroenteritis research and epidemiology, hepatitis B virus studies, and animal virus infections studies.

Frequent co-authors who have collaborated extensively with Fengcai Zhu include:

  • Jingxin Li
  • Hongxing Pan
  • Xiling Guo
  • Lunbiao Cui
  • Pengfei Jin

Their research has been published repeatedly in several key venues such as:

  • Human Vaccines & Immunotherapeutics
  • bioRxiv (Cold Spring Harbor Laboratory)
  • PubMed
  • The Lancet Infectious Diseases
  • Expert Review of Vaccines

Selected recent papers authored by Fengcai Zhu illustrate the scope and focus of their research:

  • Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial (2020) published in The Lancet Infectious Diseases
  • Co-infection with respiratory pathogens among COVID-2019 cases (2020) published in Virus Research
  • Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China (2020) published in The Journal of Infectious Diseases
  • Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials (2021) published in The Lancet Infectious Diseases
  • Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial (2021) published in The Lancet

Best Publications

  • Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

    Yanjun Zhang;Gang Zeng;Hongxing Pan;Changgui Li

  • Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial

    Feng-Cai Zhu;Jun Zhang;Xue-Feng Zhang;Cheng Zhou

  • Co-infection with respiratory pathogens among COVID-2019 cases.

    Xiaojuan Zhu;Yiyue Ge;Tao Wu;Kangchen Zhao

  • Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China

    Fengcai Zhu;Wenbo Xu;Jielai Xia;Zhenglun Liang

  • Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Feng-Cai Zhu;Feng-Cai Zhu;Fan-Yue Meng;Jing-Xin Li;Jing-Xin Li;Xiu-Ling Li

  • A Novel Influenza A (H1N1) Vaccine in Various Age Groups

    Feng-Cai Zhu;Hua Wang;Han-Hua Fang;Jian Guo Yang

  • Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China

    Hua Wang;Zijian Feng;Yuelong Shu;Hongjie Yu

  • Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China.

    Ying Chi;Yiyue Ge;Bin Wu;Wenshuai Zhang

  • Long-Term Efficacy of a Hepatitis E Vaccine

    Jun Zhang;Xue-Feng Zhang;Shou-Jie Huang;Ting Wu

  • Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

    Xiao-Feng Liang;Hua-Qing Wang;Jun-Zhi Wang;Han-Hua Fang

  • Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial

    Ming Zeng;Xu-Hu Mao;Jing-Xin Li;Wen-De Tong

  • Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation

    Xian Qi;Yan-Hua Qian;Chang-Jun Bao;Xi-Ling Guo

  • Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial

    Feng-Cai Zhu;Alie H Wurie;Li-Hua Hou;Qi Liang

  • Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

    Feng-Cai Zhu;Li-Hua Hou;Jing-Xin Li;Shi-Po Wu

  • Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9) virus.

    Lunbiao Cui;Di Liu;Weifeng Shi;Jingcao Pan

  • Profile of Acute Infectious Markers in Sporadic Hepatitis E

    Shoujie Huang;Xuefeng Zhang;Hanmin Jiang;Qiang Yan

  • Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

    You-Lin Qiao;Ting Wu;Rong-Cheng Li;Yue-Mei Hu

  • A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

    Yiyue Ge;Tingzhong Tian;Suling Huang;Fangping Wan

  • An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.

    Yiyue Ge;Tingzhong Tian;Suling Huang;Fangping Wan

  • Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.

    Jingxin Li;Aimin Hui;Xiang Zhang;Yumei Yang

Frequent Co-Authors

Ningshao Xia
Ningshao Xia Xiamen University
Jun Zhang
Jun Zhang Xiamen University
Zhibin Hu
Zhibin Hu Nanjing Medical University
Hui Zhuang
Hui Zhuang Peking University
Xin Yao
Xin Yao Lingnan University
George F. Gao
George F. Gao Chinese Center For Disease Control and Prevention
Yanping Li
Yanping Li Harvard University
Hongbing Shen
Hongbing Shen Nanjing Medical University
Jinghua Yan
Jinghua Yan Chinese Academy of Sciences
Bin Liu
Bin Liu National University of Singapore

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens up diverse career opportunities, many of which overlap with the broader healthcare and scientific fields. For those interested in patient-centered roles, exploring how to become a functional medicine nurse could be a valuable pathway. This role combines a strong biomedical background with holistic patient care, bridging microbiology and clinical practice.

On the administrative side of healthcare, professionals who specialize in medical data play an essential role. Individuals curious about salary expectations might look into the cpc medical coding salary to understand the financial benefits of coding roles that require precision and knowledge of medical terminology.

Advancing this focus on data, healthcare information management salary and career guides reveal the importance of managing medical records, compliance, and patient information systems. This is a growing sector with increasing demand for experts who can oversee complex healthcare data.

For those looking to build credentials, enrolling in the best online health information management degree cahiim accredited programs offers flexibility and industry-recognized certification. This combination of microbiology knowledge with information management skills can lead to rewarding positions in healthcare, research, and administration.

Best Scientists Citing Fengcai Zhu

Trending Scientists

Recently Published Articles